Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report

Kayo Inoue; Hiroshi Tsubamoto; Tomoko Ueda; Chihiro Tajima; Nami Nakagomi

doi:10.1016/j.gore.2020.100563

Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report

Gynecol Oncol Rep. 2020 Apr 5:32:100563. doi: 10.1016/j.gore.2020.100563. eCollection 2020 May.

Authors

Kayo Inoue¹, Hiroshi Tsubamoto¹, Tomoko Ueda¹, Chihiro Tajima¹, Nami Nakagomi²

Affiliations

¹ Department of Obstetrics and Gynecology, Hyogo College of Medicine, Japan.
² Department of Surgical Pathology, Hyogo College of Medicine, Japan.

Abstract

A germline pathogenic variant in BRCA2 was secondarily found through genomic sequencing of uterine serous carcinoma. Clinical response to olaparib was observed in recurrent uterine serous carcinoma with a germline BRCA2 mutation. Here, we report, for the first time, a long-term clinical response to olaparib in a patient with uterine serous carcinoma and a germline pathogenic BRCA2 variant.

Keywords: Germline BRCA2 mutation; Olaparib; Uterine serous carcinoma.